Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 4:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 2,287 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fasted State Clear all

Conditions: Prostate Cancer
Interventions: rhPSMA-7.3 (18F); Drug
Lead sponsor: MidLantic Urology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Bala-Cynwyd, Pennsylvania

Conditions: Healthy
Interventions: Abrika Bupropion 150 mg Extended-Released Tablet, Wellbutrin SR® 150 mg Extended-Release Tablet, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Fort Myers, Florida

Conditions: Type 1 Diabetes Mellitus
Interventions: Omnipod Insulin Management System; Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 1 Year to 8 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Healthy, Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions: Not listed
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 395 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2028
U.S. locations: 1
States / cities: Davis, California

Conditions: Prediabetes
Interventions: CGM-guided care; Behavioral
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Bloomington, Minnesota

Conditions: Hepatic Impairment
Interventions: Lemborexant; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Peripheral Arterial Disease
Interventions: Dipyridamole 200mg and Aspirin 25mg bid:, Dipyridamole 200 mg bid, Aspirin 25 mg bid; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 79 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Volunteers in Fed and Fasted State
Interventions: Zelquistinel 3 mg, Zelquistinel 10 mg; Drug
Lead sponsor: Syndeio Biosciences, Inc; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Non-alcoholic Fatty Liver Disease, Metabolic Syndrome, Metabolically Abnormal Obesity, Metabolically Normal Obesity, Obesity
Interventions: Weight loss; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 90 Years
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hepatic Impairment
Interventions: Enasidenib; Drug
Lead sponsor: Celgene; Industry
Eligibility: 40 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Lakewood, Colorado • Miami, Florida • Orlando, Florida + 2 more

Conditions: Type 1 Diabetes, Obesity
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: New York, New York

Conditions: Brain Metastases
Interventions: 18F-Fluciclovine (Axumin) PET/CT; Diagnostic Test
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Healthy
Interventions: Gabapentin 800 mg tablets, single dose (1 tablet), NEURONTIN® 400 mg capsules, single dose (2 capsules); Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Ulcerative Colitis
Interventions: Balsalazide; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pharmacokinetics and Pharmacodynamics
Interventions: Fentanyl, Fentanyl Citrate; Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Prostate Neoplasms
Interventions: Abiraterone acetate, Prednisone, Dextromethorphan hydrobromide, Theophylline; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Beverly Hills, California • San Antonio, Texas

Conditions: Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
Interventions: Health Coaching, Prolonged Overnight Fasting (POF), Mediterranean Diet, Supportive Materials; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Small Bowel Bacterial Overgrowth, Gastrointestinal Diseases, Stomach Diseases, Digestive System Diseases
Interventions: Xifaxan, SmartPill, Lactulose hydrogen breath test (H_2BT); Drug · Device · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Schizophrenia
Interventions: 10 mg CVL-231 as IR formulation, 30 mg CVL-231 as slow-release MR formulation, 30 mg CVL-231 as medium release MR formulation, 30 mg CVL-231 as fast release MR formulation, 30 mg CVL-231 Target Release, Fasted, 30 mg CVL-231 Target Release, Fed; Drug
Lead sponsor: Cerevel Therapeutics, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Improving Cardiometabolic Outcomes in Adults
Interventions: Melatonin 1 mg, Placebos, Meal Timing, NON Meal Timing; Dietary Supplement · Other
Lead sponsor: Northwestern University; Other
Eligibility: 35 Years to 54 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy
Interventions: Sertraline HCl 100 mg tablets, single dose, Zoloft® 100 mg tablets, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Healthy Volunteer
Interventions: GSK1349572, Placebo, Omeprazole; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Spinal Cord Injury
Interventions: 2 hour Oral Glucose Tolerance Test, Fat Meal Test; Procedure
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 45 Years to 75 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 2
States / cities: West Orange, New Jersey • The Bronx, New York

Search by objective public record fields.

Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management

A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fasting Conditions

Fast Track CSII Using a Novel Device in Young Children With Newly Diagnosed T1DM

Elucidation of Breast Milk Composition and Structure Over the First Year of Lactation: UC Davis Lactation Study

Returning to Normoglycemia With Targeted Use of Real-time CGM Data and Nutrition-focused Lifestyle Changes

Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects

The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD)

Pharmacokinetics of Zelquistinel in Fasted or Fed State

Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk

A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.

PET Scan Imaging of Beta Cell Mass

Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis

A Relative Bioavailability Study of Gabapentin 800 mg Tablets Under Fasting Conditions

Bioequivalency Study of Balsalazide Capsules Under Fasting Conditions

Fentanyl Sublingual Spray and Fentanyl Citrate Intravenous (IV) in Opioid Naive Subjects

A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer

FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease

Transit Time and Bacterial Overgrowth Using SmartPill Capsule

Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants

Strengthening Circadian Signals

A Relative Bioavailability Study of Sertraline HCl 100 mg Tablets Under Fasting Conditions

Bioequivalence Study of Fosinopril Sodium/ Hydrochlorothiazide 20/ 12.5 mg Tablets Under Fasting Conditions

GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose Study

Cardiovascular Disease Study